Exenatide vs Liraglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicExenatideLiraglutide
What it is

A GLP-1 receptor agonist. The label states that its amino acid sequence partly overlaps that of human GLP-1.1

A GLP-1 receptor agonist. The label describes it as an acylated human GLP-1 receptor agonist with 97% amino acid sequence similarity to natural human GLP-1.6

FDA status

FDA-approved

FDA-approved as Byetta, Bydureon and generic exenatide1,2,3,4,5

FDA-approved. Drugs@FDA lists Byetta (first approved April 28, 2005), Bydureon (January 27, 2012), Bydureon BCise (October 20, 2017) and a generic application (November 19, 2024). The cited generic label has no boxed warning.1,2,3,4,5

Is exenatide FDA-approved?

FDA-approved

FDA-approved as Victoza, Saxenda and generic versions6,7,8,9

FDA-approved. Drugs@FDA lists Victoza (first approved January 25, 2010), Saxenda (December 23, 2014) and generic liraglutide applications, the first approved December 23, 2024. The label carries a boxed warning about thyroid C-cell tumors in rodents.6,7,8,9

Is liraglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.10

Not among the six peptides the policy lists.10

FDA compounding safety-risk page

Not addressed in this profile’s sources.

Not addressed in this profile’s sources.

Kinds of studies cited

Large randomized human trials

  • Large randomized human trial EXSCEL: a randomized, placebo-controlled cardiovascular outcomes trial of a longer-acting exenatide product in 14,752 adults with type 2 diabetes, followed for a median of 3.2 years.11
  • Large randomized human trial Three 30-week randomized, double-blind, placebo-controlled trials described in the label, which together randomized 1,446 adults whose type 2 diabetes was not controlled by metformin, a sulfonylurea or both.1
  • Controlled human trial A 24-week randomized, double-blind, placebo-controlled trial in 232 adults with type 2 diabetes in which exenatide was the only diabetes medicine.1

Large randomized human trials

  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 3,731 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes.6
  • Large randomized human trial A 56-week randomized, double-blind, placebo-controlled weight trial in 635 adults with type 2 diabetes and overweight or obesity.6
  • Large randomized human trial LEADER, a double-blind, randomized, placebo-controlled cardiovascular outcomes trial in 9,340 adults with type 2 diabetes and high cardiovascular risk, published in The New England Journal of Medicine.12
  • Controlled human trial A 56-week randomized, double-blind, placebo-controlled trial in 251 adolescents aged 12 to 17 with obesity (NCT02918279).6
Records collected

50 ClinicalTrials.gov records and 49 PubMed records collected

82 ClinicalTrials.gov records and 58 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight6

Latest dated events
  1. FDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.13
  2. DailyMed publishes the generic exenatide label version cited on this page.1
  3. FDA approves a generic exenatide application, according to Drugs@FDA.5
  1. DailyMed publishes the liraglutide label version cited on this page.6
  2. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.14
  3. FDA asks the makers of Saxenda, Wegovy and Zepbound to remove a suicidal thoughts and behavior warning from their labels.15

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Exenatide injection · SPL version 17 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  4. 4
    Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  5. 5
    Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Liraglutide injection, solution · SPL version 6 · published 2026-07-14 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  7. 7
    Drugs@FDA application NDA022341 · original submission status AP · 2010-01-25 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    Drugs@FDA application NDA206321 · original submission status AP · 2014-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  9. 9
    Drugs@FDA application ANDA215503 · original submission status AP · 2024-12-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  10. 10
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  11. 11
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL, 2017) · PMID 28910237 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  12. 12
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER, 2016) · PMID 27295427 ↗

    The New England Journal of Medicine · Official source · Source checked November 14, 2026

  13. 13
    Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗

    Federal Register via GovInfo · Official source · Source checked November 14, 2026

  14. 14
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  15. 15
    FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026